Five Unicorns
Arcturus, BioNtech, Curevac, Moderna and Translate Bio
These five majors are the main state-of-art companies ate the forefront in the field of mRNA science
All of them are now developing mRNA-based vaccine candidates against SARS-CoV2 and have reached the clinical phases
These programs could lead to a short-term boost for these companies’ shares.
We are sharing with you the main assets and strengths of these companies in our latest report
“Five Unicorns in the Race for a mRNA-based vaccine against SARS-COV2”
(updated 20th September 2020)
The publication lists and develops
-General Informations on each company (location, website, FTE, top management +email/contact)
-Core business in the Field of interest and Corporate informations
-Recent Fundings and Financial Highlights (grants, funding rounds, revenues, R&D and various expenses)
-Pipeline (major indications, mechanism of action, development phases and other details)
-Clinical Trials (latest phases of developement, phase, status…)
-Latest company’s development
-Latest relevant scientific publications
See Sample Pages (http://biopharmanalyses.fr/wp-content/uploads/2020/07/sample-pages.pdf)
(Should you wish further information or order, click on http://biopharmanalyses.fr/product/four-unicorns-in-the-race-for-a-mrna-based-vaccine-against-covid-19/ )